Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06083896

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Patrick Lin, MD

CONTACT

[email protected]

713-745-0088

Patrick Lin, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objectives

  • Evaluate whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure

Secondary Objectives

  • Evaluate whether the procedure relieves pain
  • Evaluate radiographic stability of the implant
  • Evaluate functional outcome at earlier time points (2 weeks or 6 weeks) and at 6 months and possibly later time points
  • Evaluate reoperation rate and complications

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have a histologically confirmed malignancy from prior biopsy of the primary tumor or a metastatic site. Patients with carcinoma, myeloma, and lymphoma may be included in the study. Patients should have metastatic involvement of the periacetabular region that is visible radiographically. Biopsy of acetabular disease is not required for this study.
  • Age ≥18 years (Illuminoss is approved only for skeletally mature patients)
  • Suitable candidate for general anesthesia
  • Ability to understand and the willingness to sign a written informed consent document.
  • Able and willing to fill out pre-operative and post-operative functional outcome surveys
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelets ≥ 50,000/mcL

Exclusion criteria

  • Patients with uncontrolled intercurrent illness (e.g., recent pneumonia or myocardial infarction that would significantly increase risk of general anesthesia)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because of the risk of general anesthesia and radiation exposure (fluoroscopy) to the fetus
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to dental resins or PET.

Treatment and study plan

Photodynamic nails

Procedure

stab incision is made at the entry site

Primary outcomes

  1. Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion, up to one year

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick Lin, MD

CONTACT

[email protected]

(713) 745-0088

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2029
First posted
Oct 16, 2023
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.